Risk of New Bloodstream Infections and Mortality Among People Who Inject Drugs With Infective Endocarditis

Charlie Tan, Esfandiar Shojaei, Joshua Wiener, Meera Shah, Sharon Koivu, Michael Silverman, Charlie Tan, Esfandiar Shojaei, Joshua Wiener, Meera Shah, Sharon Koivu, Michael Silverman

Abstract

Importance: People who inject drugs (PWID) who are being treated for infective endocarditis remain at risk of new bloodstream infections (BSIs) due to ongoing intravenous drug use (IVDU).

Objectives: To characterize new BSIs in PWID receiving treatment for infective endocarditis, to determine the clinical factors associated with their development, and to determine whether new BSIs and treatment setting are associated with mortality.

Design, setting, and participants: This retrospective cohort study was performed at 3 tertiary care hospitals in London, Ontario, Canada, from April 1, 2007, to March 31, 2018. Participants included a consecutive sample of all PWID 18 years or older admitted with infective endocarditis. Data were analyzed from April 1, 2007, to June 29, 2018.

Main outcomes and measures: New BSIs and factors associated with their development, treatment setting of infective endocarditis episodes (ie, inpatient vs outpatient), and 90-day mortality.

Results: The analysis identified 420 unique episodes of infective endocarditis in 309 PWID (mean [SD] patient age, 35.7 [9.7] years; 213 episodes [50.7%] involving male patients), with 82 (19.5%) complicated by new BSIs. There were 138 independent new BSIs, of which 68 (49.3%) were polymicrobial and 266 were unique isolates. Aerobic gram-negative bacilli (143 of 266 [53.8%]) and Candida species (75 of 266 [28.2%]) were the most common microorganisms. Ongoing inpatient IVDU was documented by a physician in 194 infective endocarditis episodes (46.2%), and 127 of these (65.5%) were confirmed by urine toxicology results. Multivariable time-dependent Cox regression demonstrated that previous infective endocarditis (hazard ratio [HR], 1.89; 95% CI, 1.20-2.98), inpatient treatment (HR, 4.49; 95% CI, 2.30-8.76), and physician-documented inpatient IVDU (HR, 5.07; 95% CI, 2.68-9.60) were associated with a significantly higher rate of new BSIs, whereas inpatient addiction treatment was associated with a significantly lower rate (HR, 0.53; 95% CI, 0.32-0.88). New BSIs were not significantly associated with 90-day mortality (HR, 1.76; 95% CI, 0.78-4.02); significant factors associated with mortality included inpatient infective endocarditis treatment (HR, 3.39; 95% CI, 1.53-7.53), intensive care unit admission (HR, 9.51; 95% CI, 4.91-18.42), and methicillin-resistant Staphylococcus aureus infective endocarditis (HR, 1.77; 95% CI, 1.03-3.03), whereas right-sided infective endocarditis was associated with a significantly lower mortality rate (HR, 0.41; 95% CI, 0.25-0.67).

Conclusions and relevance: In this study, new BSIs were common in PWID receiving parenteral treatment for infective endocarditis. Discharging patients to outpatient treatment was not associated with an increase in new BSI incidence or mortality; carefully selected PWID may therefore be considered for such treatment.

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

References

    1. Weir MA, Slater J, Jandoc R, Koivu S, Garg AX, Silverman M. The risk of infective endocarditis among people who inject drugs: a retrospective, population-based time series analysis. CMAJ. 2019;191(4):E93-E99. doi:10.1503/cmaj.180694
    1. Hartman L, Barnes E, Bachmann L, Schafer K, Lovato J, Files DC. Opiate injection-associated infective endocarditis in the southeastern United States. Am J Med Sci. 2016;352(6):603-608. doi:10.1016/j.amjms.2016.08.010
    1. Cooper HL, Brady JE, Ciccarone D, Tempalski B, Gostnell K, Friedman SR. Nationwide increase in the number of hospitalizations for illicit injection drug use-related infective endocarditis. Clin Infect Dis. 2007;45(9):1200-1203. doi:10.1086/522176
    1. Fleischauer AT, Ruhl L, Rhea S, Barnes E. Hospitalizations for endocarditis and associated health care costs among persons with diagnosed drug dependence—North Carolina, 2010-2015. MMWR Morb Mortal Wkly Rep. 2017;66(22):569-573. doi:10.15585/mmwr.mm6622a1
    1. Wurcel AG, Anderson JE, Chui KK, et al. . Increasing infectious endocarditis admissions among young people who inject drugs. Open Forum Infect Dis. 2016;3(3):ofw157. doi:10.1093/ofid/ofw157
    1. Schranz AJ, Fleischauer A, Chu VH, Wu LT, Rosen DL. Trends in drug use–associated infective endocarditis and heart valve surgery, 2007 to 2017: a study of statewide discharge data. Ann Intern Med. 2019;170(1):31-40. doi:10.7326/M18-2124
    1. Iversen K, Ihlemann N, Gill SU, et al. . Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380(5):415-424. doi:10.1056/NEJMoa1808312
    1. Paladino JA, Poretz D. Outpatient parenteral antimicrobial therapy today. Clin Infect Dis. 2010;51(suppl 2):S198-S208. doi:10.1086/653520
    1. Tice AD, Rehm SJ, Dalovisio JR, et al. ; IDSA . Practice guidelines for outpatient parenteral antimicrobial therapy: IDSA guidelines. Clin Infect Dis. 2004;38(12):1651-1672. doi:10.1086/420939
    1. MacKenzie M, Rae N, Nathwani D. Outcomes from global adult outpatient parenteral antimicrobial therapy programmes: a review of the last decade. Int J Antimicrob Agents. 2014;43(1):7-16. doi:10.1016/j.ijantimicag.2013.09.006
    1. Pericà S JM, Llopis J, González-Ramallo V, et al. ; Spanish Collaboration on Endocarditis-Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España (GAMES) Investigators . Outpatient parenteral antibiotic treatment for infective endocarditis: a prospective cohort study from the GAMES cohort. Clin Infect Dis. 2019;69(10):1690-1700. doi:10.1093/cid/ciz030
    1. Seaton RA, Barr DA. Outpatient parenteral antibiotic therapy: principles and practice. Eur J Intern Med. 2013;24(7):617-623. doi:10.1016/j.ejim.2013.03.014
    1. Andrews MM, von Reyn CF. Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve infective endocarditis. Clin Infect Dis. 2001;33(2):203-209. doi:10.1086/321814
    1. Norris AH, Shrestha NK, Allison GM, et al. . 2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy. Clin Infect Dis. 2019;68(1):e1-e35. doi:10.1093/cid/ciy745
    1. Rodger L, Glockler-Lauf SD, Shojaei E, et al. . Clinical characteristics and factors associated with mortality in first-episode infective endocarditis among persons who inject drugs. JAMA Netw Open. 2018;1(7):e185220. doi:10.1001/jamanetworkopen.2018.5220
    1. Vandenbroucke JP, von Elm E, Altman DG, et al. ; STROBE Initiative . Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg. 2014;12(12):1500-1524. doi:10.1016/j.ijsu.2014.07.014
    1. Li JS, Sexton DJ, Mick N, et al. . Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633-638. doi:10.1086/313753
    1. Tan C, Hansen M, Cohen G, Boyle K, Daneman N, Adhikari NK. Accuracy of administrative data for identification of patients with infective endocarditis. Int J Cardiol. 2016;224:162-164. doi:10.1016/j.ijcard.2016.09.030
    1. Centers for Disease Control and Prevention. FAQs: bloodstream infection (BSI) events: central line–associated bloodstream infection and non—central line–associated bloodstream infection. Reviewed April 14, 2020. Accessed May 12, 2019.
    1. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165(6):710-718. doi:10.1093/aje/kwk052
    1. Jones M, Fowler R. Immortal time bias in observational studies of time-to-event outcomes. J Crit Care. 2016;36:195-199. doi:10.1016/j.jcrc.2016.07.017
    1. Boucher HW, Talbot GH, Bradley JS, et al. . Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1-12. doi:10.1086/595011
    1. Barter DM, Johnston HL, Williams SR, Tsay SV, Vallabhaneni S, Bamberg WM. Candida bloodstream infections among persons who inject drugs: Denver metropolitan area, Colorado, 2017-2018. MMWR Morb Mortal Wkly Rep. 2019;68(12):285-288. doi:10.15585/mmwr.mm6812a3
    1. Tobudic S, Forstner C, Burgmann H, et al. . Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna. Clin Infect Dis. 2018;67(5):795-798. doi:10.1093/cid/ciy279
    1. Grewal HK, Ti L, Hayashi K, Dobrer S, Wood E, Kerr T. Illicit drug use in acute care settings. Drug Alcohol Rev. 2015;34(5):499-502. doi:10.1111/dar.12270
    1. Rosenthal ES, Karchmer AW, Theisen-Toupal J, Castillo RA, Rowley CF. Suboptimal addiction interventions for patients hospitalized with injection drug use-associated infective endocarditis. Am J Med. 2016;129(5):481-485. doi:10.1016/j.amjmed.2015.09.024
    1. Serota DP, Niehaus ED, Schechter MC, et al. . Disparity in quality of infectious disease vs addiction care among patients with injection drug use–associated Staphylococcus aureus bacteremia. Open Forum Infect Dis. 2019;6(7):ofz289. doi:10.1093/ofid/ofz289
    1. Sharma M, Lamba W, Cauderella A, Guimond TH, Bayoumi AM. Harm reduction in hospitals. Harm Reduct J. 2017;14(1):32. doi:10.1186/s12954-017-0163-0
    1. Straw S, Baig MW, Gillott R, et al. . Long-term outcomes are poor in intravenous drug users following infective endocarditis, even after surgery. Clin Infect Dis. 2019;ciz869. doi:10.1093/cid/ciz869
    1. Thakarar K, Rokas KE, Lucas FL, et al. . Mortality, morbidity, and cardiac surgery in injection drug use (IDU)–associated versus non-IDU infective endocarditis: the need to expand substance use disorder treatment and harm reduction services. PLoS One. 2019;14(11):e0225460. doi:10.1371/journal.pone.0225460
    1. Goodman-Meza D, Weiss RE, Gamboa S, et al. . Long term surgical outcomes for infective endocarditis in people who inject drugs: a systematic review and meta-analysis. BMC Infect Dis. 2019;19(1):918. doi:10.1186/s12879-019-4558-2
    1. Leahey PA, LaSalvia MT, Rosenthal ES, Karchmer AW, Rowley CF. High morbidity and mortality among patients with sentinel admission for injection drug use-related infective endocarditis. Open Forum Infect Dis. 2019;6(4):ofz089. doi:10.1093/ofid/ofz089
    1. Rudasill SE, Sanaiha Y, Mardock AL, et al. . Clinical outcomes of infective endocarditis in injection drug users. J Am Coll Cardiol. 2019;73(5):559-570. doi:10.1016/j.jacc.2018.10.082
    1. Suzuki J, Johnson J, Montgomery M, Hayden M, Price C. Outpatient parenteral antimicrobial therapy among people who inject drugs: a review of the literature. Open Forum Infect Dis. 2018;5(9):ofy194. doi:10.1093/ofid/ofy194
    1. Eaton EF, Mathews RE, Lane PS, et al. . A 9-point risk assessment for patients who inject drugs and require intravenous antibiotics: focusing inpatient resources on patients at greatest risk of ongoing drug use. Clin Infect Dis. 2019;68(6):1041-1043. doi:10.1093/cid/ciy722
    1. Fanucchi LC, Walsh SL, Thornton AC, Nuzzo PA, Lofwall MR. Outpatient parenteral antimicrobial therapy plus buprenorphine for opioid use disorder and severe injection-related infections. Clin Infect Dis. 2020;70(6):1226-1229. doi:10.1093/cid/ciz654
    1. Buehrle DJ, Shields RK, Shah N, Shoff C, Sheridan K. Risk factors associated with outpatient parenteral antibiotic therapy program failure among intravenous drug users. Open Forum Infect Dis. 2017;4(3):ofx102. doi:10.1093/ofid/ofx102

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다